Using the SEER-Medicare Data to Assess Incident Chronic Myeloid Leukemia and Bladder Cancer Cases Missed by Cancer Registries. Issue 55 (15th May 2020)

• Record Type: Journal Article
• Authors: Lam, Clara J K; Warren, Joan L; Nielsen, Matthew; Smith, Angela; Boyd, Eric; Barrett, Michael J; Mariotto, Angela B
• Is Part Of: Journal of the National Cancer Institute. Issue 55(2020)
• Page Start: 31
• Page End: 38
• Publication Date: 2020-05-15
• Subjects: Cancer -- Periodicals; Cancer -- Congresses; 616.994
• DOI: 10.1093/jncimonographs/lgz033
• Languages: English
• ISSNs: 1052-6773

Abstract

Abstract: The growing use of oral systemic therapies and transition of some cancer treatments to the outpatient setting makes capturing all cancer case patients more difficult. We aim to develop algorithms to identify potentially missed incident case patients and estimate impact on incidence rates. We reviewed claims from SEER-Medicare 5% noncancer control patient sample to identify potentially missed chronic myeloid leukemia (CML) and bladder case patients based on diagnosis codes, cancer-related treatments, and oncology consultations. Observed rates of definite missed CML and definite and probable missed bladder case patients were calculated and the impact of missed case patients of these two cancers on SEER 65+ incidence rates were estimated. From 2008 to 2015, the algorithm estimated 781 definite CML case patients missed, increasing the number by 10.7%. From 2007 to 2015, the algorithm estimated 4629 definite and 5772 probable bladder case patients missed, increasing the number by 3.8% to 8.1%. Our algorithms offer potential methods for identifying missed case patients and validating the completeness of cancer registries.